Mitomycin C: a promising agent for the treatment of canine corneal scarring

Gupta, Rangan, Yarnall, Benjamin W., Giuliano, Elizabeth A., Kanwar, Jagat R., Buss, Dylan G. and Mohan, Rajiv R. 2011, Mitomycin C: a promising agent for the treatment of canine corneal scarring, Veterinary ophthalmology, vol. 14, no. 5, pp. 304-312.

Attached Files
Name Description MIMEType Size Downloads

Title Mitomycin C: a promising agent for the treatment of canine corneal scarring
Author(s) Gupta, Rangan
Yarnall, Benjamin W.
Giuliano, Elizabeth A.
Kanwar, Jagat R.
Buss, Dylan G.
Mohan, Rajiv R.
Journal name Veterinary ophthalmology
Volume number 14
Issue number 5
Start page 304
End page 312
Total pages 9
Publisher Wiley
Place of publication London, England
Publication date 2011
ISSN 1463-5216
Keyword(s) canine
cornea
fibroblasts
fibrosis
mitomycin C
Summary Objective  To evaluate the safety and efficacy of mitomycin C (MMC) in prevention of canine corneal scarring.

Methods  With an in vitro approach using healthy canine corneas, cultures of primary canine corneal fibroblasts or myofibroblasts were generated. Primary canine corneal fibroblasts were obtained by growing corneal buttons in minimal essential medium supplemented with 10% fetal bovine serum. Canine corneal myofibroblasts were produced by growing cultures in serum-free medium containing transforming growth factor β1 (1 ng/mL). Trypan blue assay and phase-contrast microscopy were used to evaluate the toxicity of three doses of MMC (0.002%, 0.02% and 0.04%). Real-time PCR, immunoblot, and immunocytochemistry techniques were used to determine MMC efficacy to inhibit markers of canine corneal scarring.

Results  A single 2-min treatment of 0.02% or less MMC did not alter canine corneal fibroblast or keratocyte phenotype, viability, or growth. The 0.02% dose substantially reduced myofibroblast formation (up to 67%; P < 0.001), as measured by the change in RNA and protein expression of fibrosis biomarkers (α-smooth muscle actin and F-actin).

Conclusion 
This in vitro study suggests that a single 2-min 0.02% MMC treatment to the canine corneal keratocytes is safe and may be useful in decreasing canine corneal fibrous metaplasia. In vivo studies are warranted.
Language eng
Field of Research 030401 Biologically Active Molecules
Socio Economic Objective 920107 Hearing, Vision, Speech and Their Disorders
HERDC Research category C1.1 Refereed article in a scholarly journal
Copyright notice ©2011, Wiley
Persistent URL http://hdl.handle.net/10536/DRO/DU:30056208

Document type: Journal Article
Collections: School of Medicine
Institute for Frontier Materials
Connect to link resolver
 
Unless expressly stated otherwise, the copyright for items in DRO is owned by the author, with all rights reserved.

Versions
Version Filter Type
Citation counts: TR Web of Science Citation Count  Cited 2 times in TR Web of Science
Scopus Citation Count Cited 2 times in Scopus
Google Scholar Search Google Scholar
Access Statistics: 8 Abstract Views, 0 File Downloads  -  Detailed Statistics
Created: Wed, 25 Sep 2013, 14:35:01 EST

Every reasonable effort has been made to ensure that permission has been obtained for items included in DRO. If you believe that your rights have been infringed by this repository, please contact drosupport@deakin.edu.au.